R.E.C.K vs Exparel in Robotic Nephrectomy

The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.

Trial Details

NCT ID

NCT07092566

Phase

PHASE3

Sponsor

Wake Forest University Health Sciences

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

Ropivacaine HCL
Exparel
Epinephrine
Clonidine HCL
Ketorolac

Locations (sample)

Charlotte, North Carolina, United States|35.22709,-80.84313

Key Eligibility Criteria

Ability to understand and willingness to sign an IRB-approved informed consent
Age ≥ 18 years at the time of consent.
Planned robotic partial or radical nephrectomy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →